Hjem › Livmoderslimhindekræft › Oregon
Livmoderslimhindekræft kliniske forsøg i Oregon
27 studier for Livmoderslimhindekræft søger deltagere på steder i Oregon.
Byer i Oregon
Officiel studietekst (engelsk)
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
- Saint Alphonsus Cancer Care Center-Ontario, Ontario
- Providence Portland Medical Center, Portland
- Providence Saint Vincent Medical Center, Portland
- og 1 flere
RekruttererFase 2
Alle aldre · Alle køn · Opdateret 2. okt. 2026 · NCT05564377The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- Oregon Health & Science University (OHSU), Portland
RekruttererFase 1/2
Alder 12 og opefter · Alle køn · Opdateret 2. okt. 2026 · NCT04585750Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
- Legacy Good Samaritan Hospital and Medical Center, Portland
- Providence Portland Medical Center, Portland
- Providence Saint Vincent Medical Center, Portland
- og 1 flere
RekruttererFase 3
Alder 18 og opefter · Kvinder · Opdateret 2. okt. 2026 · NCT07198074A Phase 1, First-in-Human (FIH), Open-Label, Dose-Escalation and Dose Expansion Study of the Peptide Drug Conjugate (PDC), TS-104, as a Monotherapy in Subjects With Select Advanced Solid Tumors
- Site 02, Portland
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 30. sep. 2026 · NCT07814248Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
- Providence Portland Medical Center, Portland
- Providence Saint Vincent Medical Center, Portland
RekruttererFase 2
Alder 18 og opefter · Kvinder · Opdateret 28. sep. 2026 · NCT05112601Study of AVZO-021 in Patients With Advanced Solid Tumors
- Avenzo Therapeutics Recruiting Site, Portland
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 28. sep. 2026 · NCT05867251Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors
- Research Site, Portland
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 25. sep. 2026 · NCT06218914Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER
- Providence Portland Medical Centre, Portland
- Providence Saint Vincent Medical Center, Portland
RekruttererFase 2
Alder 18 og opefter · Kvinder · Opdateret 24. sep. 2026 · NCT05640999A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
- Oncology Associates of Oregon, P.C. ( Site 8005), Eugene
RekruttererFase 3
Alder 18 og opefter · Kvinder · Opdateret 17. sep. 2026 · NCT06952504Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
- Providence Portland Medical Center, Portland
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 10. sep. 2026 · NCT06293898Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer
- Willamette Valley Cancer Institute and Research Center - Eugene, Eugene
- NW Cancer Specs. P.C., Happy Valley
- USOR - NW Cancer Specs P.C., Portland
- og 1 flere
RekruttererFase 3
Alder 18 og opefter · Kvinder · Opdateret 9. sep. 2026 · NCT07166094A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors
- Providence Cancer Institute of Oregon, Portland
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 3. sep. 2026 · NCT06515613DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
- Research Site, Eugene
RekruttererFase 3
Alder 18 og opefter · Kvinder · Opdateret 3. sep. 2026 · NCT06989112Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
- Research Site, Portland
RekruttererFase 1/2
Alder 18 til 130 · Alle køn · Opdateret 21. aug. 2026 · NCT05797168FOG-001 in Locally Advanced or Metastatic Solid Tumors
- Oregon Health and Science University, Portland
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 17. aug. 2026 · NCT05919264A Study of MGC026 in Participants With Advanced Solid Tumors
- Providence Cancer Institute, Portland
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 11. aug. 2026 · NCT06242470Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
- USOR Oncology Associates of Oregon, P.C., Eugene
- Compass Oncology - Rose Quarter, Portland
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 4. aug. 2026 · NCT05579366A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
- Oregon Health & Science University, Portland
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 30. jul. 2026 · NCT04657068Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
- Research Site, Eugene
- Research Site, Portland
RekruttererFase 3
Alder 18 og opefter · Kvinder · Opdateret 29. jul. 2026 · NCT07044336Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors
- Investigative Site #121, Portland
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 23. jul. 2026 · NCT06974110Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers
- 517, Eugene
RekruttererFase 2
Alder 18 og opefter · Kvinder · Opdateret 16. jul. 2026 · NCT06906341First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
- Providence Cancer Institute Franz Clinic, Portland
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 7. jul. 2026 · NCT05768139cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
- Oregon Health Sciences University, Portland
RekruttererObservationsstudieFrivillige med god helbredstilstand velkomne
Alder 40 og opefter · Alle køn · Opdateret 20. jan. 2026 · NCT05366881Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With Advanced/Recurrent Endometrial Cancer
- Oncology Associates of Oregon, P.C., Eugene
- Northwest Cancer Specialists, P.C., Portland
RekruttererFase 2
Alder 18 og opefter · Kvinder · Opdateret 24. dec. 2025 · NCT06463028SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Portland
RekruttererObservationsstudie
Alle aldre · Alle køn · Opdateret 28. okt. 2025 · NCT03452774A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
- Oregon Health & Science University, Portland
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 13. feb. 2025 · NCT05669430Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer
- Oncology Associates of Oregon, Eugene
- Northwest Cancer Specialists, Portland
RekruttererFase 2/3
Alder 18 og opefter · Kvinder · Opdateret 2. maj 2024 · NCT05797831Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie har sine egne kvalifikationskrav; studieteamet afgør, hvem der kan deltage.